AXL1717

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
012320112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The primary objective of this study was to compare the progression-free survival (PFS) at 12 weeks between patients… (More)
Is this relevant?
2017
2017
Purpose Early phase I study of safety of AXL1717 in patients with recurrent or progressive malignant astrocytomas and evaluation… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects. The objectives of… (More)
Is this relevant?
Review
2012
Review
2012
The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have become increasingly… (More)
Is this relevant?
2011
2011
BACKGROUND Inhibition of the Insulin-like Growth Factor-1 receptor (IGF-1R) has resulted in extensive anti-tumor effects… (More)
Is this relevant?
2011
2011
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of the new anticancer agent picropodophyllin… (More)
  • figure 1
  • table 1
  • table 4
  • figure 6
Is this relevant?